Apoxis S. A.
Records under this name other than patents Apoxis S. A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,736,657 | Fusion constructs containing active sections on TNF ligands Formerly held Term ended Term ended Mar 28, 2024 · USPTO record | Term ended | Term ended Mar 28, 2024 | USPTO record |
| US 7,385,032 | Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins Formerly held Term ended Term ended Aug 9, 2023 · USPTO record | Term ended | Term ended Aug 9, 2023 | USPTO record |
| US 7,691,804 | Baff Receptor (BCMA), an Immunoregulatory Agent Formerly held Term ended Term ended May 15, 2023 · Medium confidence | Term ended | Term ended May 15, 2023 | Medium confidence |
| US 8,501,177 | Treatment of ectodermal dysplasia with EDA1 fusion proteins Term ended Term ended Mar 20, 2023 · USPTO record | Term ended | Term ended Mar 20, 2023 | USPTO record |
| US 7,083,785 | Methods of Treatment by Administering an Anti-Bcma Antibody Formerly held Term ended Term ended Jan 4, 2022 · Medium confidence | Term ended | Term ended Jan 4, 2022 | Medium confidence |
| US 8,828,669 | Methods of Screening for a Compound That Inhibits the Interaction Between Baff and Bcma Formerly held Term ended Term ended Aug 16, 2020 · Medium confidence | Term ended | Term ended Aug 16, 2020 | Medium confidence |
| US 9,650,430 | Methods of Treating Autoimmune Diseases Using a B-Cell Maturation Antigen (BCMA) Formerly held Term ended Ended no later than Aug 16, 2020 · Low confidence | Term ended | Ended no later than Aug 16, 2020 | Low confidence |
| US 10,494,416 | Methods of Modulating Immune Responses Using Bcma Polypeptide Formerly held Term ended Term ended Aug 16, 2020 · Medium confidence | Term ended | Term ended Aug 16, 2020 | Medium confidence |
| US 7,276,241 | Methods of Treating a Tumor That Expresses April by Administering Bcma Formerly held Lapsed on the fee record Ended Oct 2, 2019 · Medium confidence | Lapsed on the fee record | Ended Oct 2, 2019 | Medium confidence |
| US 7,223,852 | Nucleic Acids Encoding Train-R: a Cysteine Rich Member of the Tnf-Receptor Family Formerly held Lapsed on the fee record Ended May 29, 2019 · Medium confidence | Lapsed on the fee record | Ended May 29, 2019 | Medium confidence |